AltruBio

BeoSpace─Three Influential Women of Biopharma Breaking Down the Executive Barrier

Scrip Asks ─ What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances

AltruBio to Present at BIO CEO & Investor Conference

BioSpace ─ BioSpace Launches 2022 Hotbed Maps to Highlight Thriving Life Sciences Clusters

AltruBio to Present at Biotech Showcase™ 2022

BioSpace ─ Top Life Sciences Startups to Watch in 2022

Life Science Leader─What Trends Are 9 Biopharma CEOs Paying Attention To?

Podcast─CMC Developability Assessments For Rapid Ph.1 Entry With AltruBio's Gene Lee, Ph.D.

AltruBio to Present Abstract on Checkpoint Regulator Neihulizumab as a Novel Therapy for Immunological Diseases at the B&T Cell-Mediated Autoimmune Disease Drug Development Virtual Summit

BioPharm International─Trends in Outsourcing of Bioprocess Development

Bioprocess Online─mAb 2.0 For Psoriatic Arthritis

Podcast─From Bayer To Startup Bio With AltruBio's Dr. Judy Chou

AltruBio Continues to Strengthen Management Team With the Appointment of Jesse Hall, M.D., as Chief Medical Officer

Fierce Biotech─AltruBio snags a CMO after pivot from oncology to immunology

Life Science Leader─Companies To Watch: AltruBio

AltruBio Strengthens Management Team With Appointment of Jeroen Grasman as Chief Financial Officer

ALTRUBIO RAISES $63 MILLION SERIES A ROUND TO CONTINUE ITS COMPANY TRANSFORMATION

Endpoints News─After a major facelift, AltruBio says it's ready for a pivotal fight against graft-versus-host disease

Fierce Biotech─New name, new board, new focus: AltruBio relaunches with $63M series A

AltruBio’s Neihulizumab Granted Fast Track Designation by the FDA for Steroid Refractory Acute Graft Versus Host Disease

AltruBio to present at Biotech Showcase Digital 2021.

AltruBio Presented its Novel PSGL-1 Agonist Antibody Program for Immunological Diseases at FOCIS and Presented its Phase 2a Psoriatic Arthritis study results for lead molecule, Neihulizumab (AbGn-168H), at ACR.

AltruBio Announces First Patient Dosed in Phase 1b Study of Neihulizumab in Patients with Steroid-Refractory Acute Graft-versus-Host Disease.

AltruBio Inc. moves forward with clinical development of Neihulizumab in Steroid-Refractory Acute Graft-versus-Host Disease after encouraging Phase 1a results

AltruBio Inc. presented AbGn-107 Phase 1a chemo-refractory GI cancer results at ASCO-GI 2020

AltruBio’s presentation on Neihulizumab Phase 2a Ulcerative colitis results selected as Poster of Distinction at Digestive Disease Week (DDW) 2020

AbGenomics Holding Inc. Announces Company Name Change to AltruBio Inc.

The Business Journals─Bayer site head in Berkeley jumps to Peninsula cancer drug developer

Abgenomics welcomes Dr. Judy Chou as new President/CEO

AbGenomics Presented Latest Research Findings on the preliminary Phase I Clinical progress of AbGn-107 at the World ADC Asia 2018

AbGenomics Highlights AbGn-107 at the 2018 Protein Engineering Summit

AbGenomics CMO Dr. Shih-Yao Lin spoke at the 6th Annual Biologics World Taiwan

FDA Grants AbGenomics AbGn-168H (Neihulizumab) Orphan Drug Designation

AbGenomics Announces FDA Acceptance to Commence Phase I Clinical Trial of AbGn-107 ADC Candidate for Pancreatic, Gastric, and Colorectal Cancer Treatments

AbGenomics Announces Promising Final Results from their Phase II Open-Label Clinical Study of AbGn-168H / Neihulizumab in Psoriatic Arthritis, a T-cell Mediated Disease

AbGenomics Announces initiation of phase-Ib/IIa clinical trial of Neihulizumab (AbGn-168H) for the treatment of steroid refractory acute GvHD (aGvHD)

AbGenomics Announces IND Filing for AbGn-168H (Neihulizumab) to Treat Psoriatic Arthritis

AbGenomics Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans

AbGn-168 Phase I Trial Initiate